Evoke Pharma and EVERSANA Announce the Appointment of Christopher Quesenberry as Chief Commercial Officer for Gimoti™
August 25 2020 - 8:30AM
Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical
company focused on treatments for gastrointestinal (GI) diseases
and EVERSANA™, a leading provider of global commercial services to
the life science industry, today announced that EVERSANA has
appointed Christopher Quesenberry as Chief Commercial Officer for
Gimoti™. In June 2020, Gimoti was approved by the Food and Drug
Administration for the relief of symptoms in adults with acute and
recurrent diabetic gastroparesis to which the companies have
partnered commercialization.
Mr. Quesenberry brings over 30 years of
experience in building and executing on commercial strategies for
pharmaceutical companies and has held roles across the breadth of
sales, marketing and operations. He previously spent 27 years
between Novo Nordisk and Merck & Co. culminating in positions
of Senior Director in Commercial Strategy, as well as Senior Sales
Director in Commercial Operations, respectively. Recently, Mr.
Quesenberry served as the Vice President of Global Commercial
Effectiveness, providing leadership for Sales, Market Access, Sales
Operations in addition to other commercial functions at Nalpropion
Pharmaceuticals.
The commercialization collaboration between
Evoke and EVERSANA calls for a wide collection of business
functions to be headed by EVERSANA. Mr. Quesenberry is
leading the commercialization efforts across multiple functional
teams driving senior decision making for strategy and guiding the
building of the sales team amongst other responsibilities.
The coordination and breadth of commercial expertise within
EVERSANA has showcased the benefits of this wide-ranging commercial
partnership in terms of execution and efficiency. The teams
are rapidly implementing the original strategy and message for
Gimoti as Evoke envisioned.
“In partnership with EVERSANA, we have been
working to on-board an exceptional team of sales and marketing
specialists in anticipation for the launch of Gimoti before and
after our FDA approval earlier this year,” commented David Gonyer,
R.Ph., President and CEO. “We are excited to bring on a seasoned
professional such as Mr. Quesenberry and believe that he will be an
invaluable addition as we continue to leverage EVERSANA’s
integrated suite of capabilities and experts. We look forward to
working with Chris in order to execute on our planned
commercialization strategy as we plan to initiate sales for Gimoti
in the fourth quarter of this year.”
Jim Lang, CEO of EVERSANA added, “Our
comprehensive integrated commercial services platform is fueled by
proven industry leaders who understand the complexities of
successful launches and ongoing commercial success. Mr. Quesenberry
will work side-by-side with Evoke leaders to deploy the right
strategies and services to make sure Gimoti reaches patients and
improves lives.”
About Evoke Pharma, Inc.
Evoke is a specialty pharmaceutical company
focused primarily on the development of drugs to treat GI disorders
and diseases. The Company developed GIMOTI, a nasal spray
formulation of metoclopramide, for the relief of symptoms
associated with acute and recurrent diabetic gastroparesis in
adults.
Diabetic gastroparesis is a GI disorder
affecting millions of patients worldwide, in which the stomach
takes too long to empty its contents resulting in serious GI
symptoms as well as other systemic complications. The gastric delay
caused by gastroparesis can compromise absorption of orally
administered medications. Prior to FDA approval to commercially
market GIMOTI, metoclopramide was only available in oral and
injectable formulations and remains the only drug currently
approved in the United States to treat gastroparesis. Visit
www.EvokePharma.com for more information.
About EVERSANA Life Science Services,
LLC
EVERSANA™ is a leading provider of global
services to the life science industry. The company’s integrated
solutions are rooted in the patient experience and span all stages
of the product lifecycle to deliver long-term, sustainable value
for patients, prescribers, channel partners and payers. The company
serves more than 500 organizations, including innovative start-ups
and established pharmaceutical companies to advance life science
solutions for a healthier world. To learn more about EVERSANA,
visit eversana.com or connect through LinkedIn and Twitter.
Safe Harbor Statement
Evoke cautions you that statements included in
this press release that are not a description of historical facts
are forward-looking statements. In some cases, you can identify
forward-looking statements by terms such as “may,” “will,”
“should,” “expect,” “plan,” “anticipate,” “could,” “intend,”
“target,” “project,” “contemplates,” “believes,” “estimates,”
“predicts,” “potential” or “continue” or the negatives of these
terms or other similar expressions. These statements are based on
the company’s current beliefs and expectations. These
forward-looking statements include statements regarding: the timing
of the commercial launch of Gimoti and commercial activities to be
conducted by EVERSANA; and the size of the gastroparesis market.
The inclusion of forward-looking statements should not be regarded
as a representation by Evoke that any of its plans will be
achieved. Actual results may differ from those set forth in this
press release due to the risks and uncertainties inherent in
Evoke’s business, including, without limitation: the ability of
Evoke and Evoke’s third party manufacturer, Patheon, to
successfully complete the commercial manufacturing of Gimoti;
Evoke’s and EVERSANA’s ability to successfully launch and drive
market demand for Gimoti and the timing thereof; Evoke’s ability to
obtain additional financing as needed to support its operations,
including through its existing line of credit with EVERSANA which
is subject to certain customary conditions; the COVID-19 pandemic
may disrupt Evoke’s, Patheon’s and EVERSANA’s business operations
impairing the ability to manufacture or commercialize Gimoti and
Evoke’s ability to generate any product revenue; Evoke’s dependence
on third parties for the manufacture of Gimoti; Evoke is entirely
dependent on the success of Gimoti; inadequate efficacy or
unexpected adverse side effects relating to Gimoti that could delay
or prevent commercialization, or that could result in recalls or
product liability claims; our ability to obtain and maintain
intellectual property protection for Gimoti; and other risks
detailed in Evoke’s prior press releases and in the periodic
reports it files with the Securities and Exchange Commission. You
are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof, and Evoke
undertakes no obligation to revise or update this press release to
reflect events or circumstances after the date hereof. All
forward-looking statements are qualified in their entirety by this
cautionary statement. This caution is made under the safe harbor
provisions of the Private Securities Litigation Reform Act of
1995.
Investor Contact:The Ruth GroupEmma PoalilloTel:
646-536-7024 epoalillo@theruthgroup.com
Evoke Pharma (NASDAQ:EVOK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Evoke Pharma (NASDAQ:EVOK)
Historical Stock Chart
From Apr 2023 to Apr 2024